Know Cancer

forgot password

C-2424: Phase II Study of Celecoxib, Capecitabine, and Irinotecan in Patients With Metastatic Colorectal Cancer

Phase 2
18 Years
Not Enrolling
Colorectal Cancer

Thank you

Trial Information

C-2424: Phase II Study of Celecoxib, Capecitabine, and Irinotecan in Patients With Metastatic Colorectal Cancer

Inclusion Criteria:

1. Patient must have a histologically proven adenocarcinoma of colon or rectum with
metastases or local recurrence.

2. Patients must have at least one measurable lesion according to the RECIST criteria.
Bone metastases, ascites and pleural effusion are not measurable.

3. Minimum indicator lesion size as follows:

Greater than or equal to 20 mm measured by conventional CT Greater than or equal to
10 mm measured by spiral techniques

4. Prior use of celecoxib for the treatment of nonmalignant disorders is allowed.

5. Patients must have a performance status of 0,1, or 2 by the Southwest Oncology Group

6. Patients must have a calculated creatinine clearance of greater than 50 ml/min.

7. Patients must have an absolute neutrophil count of greater than or equal to 1500/ml,
platelet count greater than or equal to 100,000/ml, and total serum bilirubin equal
or less than the institution's upper limit or normal range.

8. Patients must have recovered from any effects of surgery.

9. Evaluable disease must be present outside radiation field. At least 3 weeks must
have elapsed after discontinuation of radiation therapy.

10. Patients must provide a signed consent to participate in the study.

Exclusion Criteria:

1. Patients with a proven history of peptic ulcer disease or gastroesophageal reflux.

2. Patients who have experienced asthma, urticaria, or allergic-type reactions after
taking aspirin or other non-steroidal anti-inflammatory drugs.

3. Patients who have received prior chemotherapy for colorectal cancer (including
capecitabine or irinotecan) except for patients relapsing more than 6 months after
completion of adjuvant chemotherapy.

4. History of other malignancy, except for cancers that have been treated with a
curative intent and patient is without evidence of active disease.

5. Unresolved bacterial infection requiring treatment with antibiotics.

6. Pregnant or lactating women may not participate in the study. Women/men of
reproductive age group may not participate unless they have agreed to use an
effective method of contraception.

7. Patients who have allergy to any of the study drugs or sulfa drugs.

8. Patients known to have HIV-1 virus infection because of the undetermined effect of
this chemotherapy regimen in patients with HIV-1 and the potential for serious
interaction with anti-HIV medications.

9. Gilbert's disease.

10. Lack of physical integrity of the upper gastrointestinal tract. Inability to swallow
tablets or those who have malabsorption syndrome.

11. Other serious concurrent infection

12. Clinically significant cardiac disease not well controlled with medication (e.g.
congestive heart failure, symptomatic coronary artery disease and cardiac
arrhythmias) or myocardial infarction within the last 12 months.

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the objective response rate to the combination of celecoxib, capecitabine, and irinotecan in patients with metastatic colorectal cancer.

Principal Investigator

Mark Zalupski, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Michigan Cancer Center


United States: Food and Drug Administration

Study ID:

UMCC 3-24



Start Date:

June 2003

Completion Date:

March 2008

Related Keywords:

  • Colorectal Cancer
  • Colorectal Neoplasms



University of Michigan Cancer Center Ann Arbor, Michigan  48109